Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) Sees Large Growth in Short Interest

Scinai Immunotherapeutics Ltd. (NASDAQ:SCNIGet Free Report) saw a significant increase in short interest in May. As of May 31st, there was short interest totalling 4,400 shares, an increase of 633.3% from the May 15th total of 600 shares. Based on an average daily volume of 18,100 shares, the days-to-cover ratio is presently 0.2 days.

Scinai Immunotherapeutics Trading Up 4.8 %

Shares of NASDAQ SCNI traded up $0.13 during mid-day trading on Thursday, hitting $2.82. The company had a trading volume of 197,669 shares, compared to its average volume of 13,311. The company has a market capitalization of $1.31 million, a price-to-earnings ratio of -0.01 and a beta of 2.46. Scinai Immunotherapeutics has a 1 year low of $2.23 and a 1 year high of $18.70. The stock’s 50-day moving average price is $4.18 and its 200-day moving average price is $5.13.

Scinai Immunotherapeutics (NASDAQ:SCNIGet Free Report) last posted its earnings results on Wednesday, May 15th. The company reported ($240.00) EPS for the quarter.

About Scinai Immunotherapeutics

(Get Free Report)

Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications.

Read More

Receive News & Ratings for Scinai Immunotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scinai Immunotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.